Albemarle (NYSE:ALB) Stock Price Target Lowered at Royal Bank Of Canada

Albemarle (NYSE:ALB) had its price objective cut by Royal Bank Of Canada from $129.00 to $119.00 in a report released on Friday,Benzinga reports. They currently have an outperform rating on the specialty chemicals company’s stock.

Several other equities research analysts have also weighed in on ALB. Mizuho upgraded Albemarle from a “neutral” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Wednesday, October 14th. Weiss Ratings downgraded Albemarle from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Argus cut their target price on Albemarle from $230.00 to $135.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Wall Street Zen raised Albemarle from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, Truist Financial reiterated a “buy” rating and issued a $170.00 price target (down from $185.00) on shares of Albemarle in a research report on Friday. Fifteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $177.64.

Albemarle Stock Performance

Shares of ALB traded up $0.66 during mid-day trading on Friday, hitting $99.03. The company’s stock had a trading volume of 2,444,312 shares, compared to its average volume of 2,458,542. Albemarle has a one year low of $89.77 and a one year high of $221.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.35 and a current ratio of 2.09. The firm has a market capitalization of $11.69 billion, a PE ratio of 23.92, a price-to-earnings-growth ratio of 0.54 and a beta of 1.34. The stock’s 50-day moving average is $107.59 and its two-hundred day moving average is $147.87.

Albemarle (NYSE:ALB) last released its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Albemarle had a return on equity of 10.96% and a net margin of 3.09%. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.52 billion. During the same period last year, the business earned ($0.19) earnings per share. The firm’s revenue for the quarter was up 18.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Albemarle will post 11.20 EPS for the current year.

Albemarle Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, December 18th will be paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Friday, December 18th. Albemarle’s dividend payout ratio is currently 39.61%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Primecap Management Co. CA acquired a new position in shares of Albemarle in the 2nd quarter worth approximately $358,101,000. Deutsche Bank AG bought a new stake in Albemarle during the 2nd quarter worth approximately $131,049,000. Bank of New York Mellon Corp bought a new stake in Albemarle during the 2nd quarter worth approximately $103,268,000. Aberdeen Group plc increased its holdings in Albemarle by 5,344.0% during the 3rd quarter. Aberdeen Group plc now owns 753,618 shares of the specialty chemicals company’s stock valued at $79,718,000 after purchasing an additional 739,775 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Albemarle by 2,981.1% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 733,793 shares of the specialty chemicals company’s stock valued at $77,621,000 after purchasing an additional 709,977 shares in the last quarter. Institutional investors own 92.87% of the company’s stock.

Key Stories Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported third-quarter adjusted earnings of $2.58 per share, ahead of estimates, on $1.55 billion in revenue—also above forecasts and up 18.8% year over year. Higher lithium pricing, strong demand, cost reductions and improved Specialties profits supported the results. Albemarle Q3 Earnings Call Highlights Cost Discipline and Lithium Demand
• Positive Sentiment: Scotiabank maintained its “Sector Outperform” rating and $190 price target, estimating EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited current-year consensus estimate. Albemarle analyst coverage
• Positive Sentiment: Truist reaffirmed its “buy” rating, though it lowered its price target to $170 from $185. Truist rating information
• Neutral Sentiment: RBC cut its target to $119 from $129 but retained an “outperform” rating, reflecting a more cautious valuation alongside continued optimism about the shares. RBC rating information
• Negative Sentiment: Barclays lowered its target to $95 from $109 and kept an “equal weight” rating, pointing to a less favorable near-term risk-reward view. Lithium prices remain volatile, a potential source of uncertainty for earnings. Barclays rating information

About Albemarle

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.

Albemarle is one of the world’s major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.